Article | December 11, 2023

Following The Science To Develop Best-In-Class Cancer Drugs

Source: Cytiva
Antibodies And Cancer Cell GettyImages-1410479280

Accomplished biotech executive and physician Ahmed Hamdy, M.D., is determined to deliver best-in-class cancer therapeutics to save and improve patients’ lives. He and his long-time business partner Raquel Izumi, Ph.D. have co-founded multiple companies, including Acerta Pharma and most recently Vincerx Pharma. At Acerta, their lead candidate acalabrutinib (known commercially as Calquenc®) was approved by the U.S. Food and Drug Administration (FDA) in 2017 as a Bruton’s tyrosine kinase (BTK) inhibitor to treat blood cancer. In 2015, AstraZeneca acquired a majority share of Acerta for $4 billion, and Hamdy and Izumi went on to found Vincerx.

Per Hamdy, “We started the company with the premise of developing drugs for cancer, a highly unmet medical need. We have a very exciting pipeline that we acquired from Bayer that could be paradigm-shifting.” With Hamdy and Izumi’s leadership and experience in tow, multiple drugs in the Vincerx pipeline are headed toward their investigational new drug (IND) application filing and subsequent clinical phase. Download the full article to read more about how Vincerx’s lean team is striving to bring candidates to clinic as quickly as possible.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.

Subscribe to Biosimilar Development X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Biosimilar Development